Denali Therapeutics Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics or view top-rated stocks.

8 brokers have issued 1-year target prices for Denali Therapeutics' stock. Their DNLI stock forecasts range from $39.00 to $111.00. On average, they predict Denali Therapeutics' stock price to reach $79.88 in the next year. This suggests a possible upside of 158.2% from the stock's current price.
View analysts' price targets for Denali Therapeutics or view top-rated stocks among Wall Street analysts.

Denali Therapeutics' stock was trading at $44.60 at the beginning of 2022. Since then, DNLI shares have decreased by 30.7% and is now trading at $30.93.
View the best growth stocks for 2022 here.

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Denali Therapeutics.

Denali Therapeutics Inc. (NASDAQ:DNLI) issued its quarterly earnings data on Thursday, May, 5th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.06. The firm earned $42.10 million during the quarter, compared to the consensus estimate of $33.32 million. Denali Therapeutics had a negative trailing twelve-month return on equity of 28.83% and a negative net margin of 344.79%. The business's quarterly revenue was up 432.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.58) earnings per share.
View Denali Therapeutics' earnings history.

1 employees have rated Denali Therapeutics CEO Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among Denali Therapeutics' employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Denali Therapeutics include Bio-Techne (TECH), Novozymes A/S (NVZMY), Qiagen (QGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Ginkgo Bioworks (DNA), Novavax (NVAX), Ablynx (ABLYF), Abcam (ABCM), Vir Biotechnology (VIR) and Beam Therapeutics (BEAM).
View all of DNLI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG).

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Denali Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (12.19%), BlackRock Inc. (6.66%), Vanguard Group Inc. (6.60%), State Street Corp (3.11%), Gilder Gagnon Howe & Co. LLC (2.13%) and Bank of New York Mellon Corp (1.31%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends for Denali Therapeutics.

DNLI stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Prudential Financial Inc., Citigroup Inc., Baillie Gifford & Co., Integral Health Asset Management LLC, AIA Group Ltd, Principal Financial Group Inc., and UBS Group AG. Company insiders that have sold Denali Therapeutics company stock in the last two years include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato.
View insider buying and selling activity for Denali Therapeutics or view top insider-selling stocks.

DNLI stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Bank of New York Mellon Corp, Woodline Partners LP, Federated Hermes Inc., Bank of America Corp DE, Dimensional Fund Advisors LP, BlackRock Inc., and The Manufacturers Life Insurance Company .
View insider buying and selling activity for Denali Therapeutics or or view top insider-buying stocks.

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DNLI stock can currently be purchased for approximately $30.93.

Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $3.80 billion and generates $48.66 million in revenue each year. The company earns $-290.58 million in net income (profit) each year or ($2.34) on an earnings per share basis.

Denali Therapeutics employs 380 workers across the globe.

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for Denali Therapeutics is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at [email protected].